What factors counteract mid-term survival following endovascular repair of abdominal aortic aneurysms?

Ertekin Utku Ünal, Hakkı Zafer İscan, Bekir Bogachan Akkaya, Isa Civelek, Mehmet Karahan, Ece Celikten, Göktan Askin, Hayrettin Levent Mavioğlu, Mehmet Ali Özatik

Department of Cardiovascular Surgery, Ankara City Hospital, Ankara, Turkey

Kardiochir Torakochir Pol 2021; 18 (1): 8-14

Abstract

Introduction: Endovascular aortic aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) is increasingly used, and has become the standard treatment option for AAA.

Aim: To evaluate the outcomes and predictors of survival of endovascular treatment of AAA in the short- and medium-term.

Material and methods: A total of 222 patients having endovascular AAA repair between January 2013 and December 2019 by the same surgical team were included in the study. Patient demographics, perioperative and follow-up data including mortality, complications, and need for secondary intervention were collected. The primary endpoint was all-cause mortality. Kaplan-Meier analysis was conducted for survival and Cox regression models were assessed for predictors of survival.

Results: The median age was 70 years, with male predominance (202 patients, 91%). Thirty-day mortality was 1.8%. Median follow-up to the primary endpoint was 20 months (range: 1–80 months). Survival rates at 1, 3, and 5 years were 93.5%, 81.4%, and 62.2%, respectively. Freedom from secondary intervention rates were 95.5% at 1 year, 88.7% at 3 years, and 82.1% at 5 years. Cox proportional hazard models showed that preoperative creatinine levels \( \geq \) 1.8 mg/dl (hazard ratio (HR) = 2.68, 95% CI: 1.21–6.42, \( p = 0.027 \)), haemoglobin levels < 10 gr/dl (HR = 3.38, 95% CI: 1.16–9.90, \( p = 0.026 \)), ejection fraction < 30% (HR = 5.67, 95% CI: 1.29–24.86, \( p = 0.021 \)), and AAA diameter \( \geq \) 6.0 cm (HR = 2.20, 95% CI: 1.01–4.81, \( p = 0.049 \)) were independently associated with mid-term survival.

Conclusions: EVAR is a safe procedure with low postoperative morbidity and mortality. This study confirms that the mid-term survival and results are favourable. However, the analysed factors in this study that predict reduced survival (high preoperative creatinine, low haemoglobin, low ejection fraction and larger aneurysms) should be judged when planning endovascular repair of AAA.

Key words: abdominal aortic aneurysm, aneurysm sac, endovascular aneurysm repair, mortality, reintervention.

Reference:

Introduction

Endovascular aneurysm repair (EVAR) has become the preferred treatment modality for abdominal aortic aneurysm (AAA) [1, 2]. It is recognized that early and late outcome after endovascular procedures is comparable to and even better than open surgery to some extent [3–5]. There are some controversial arguments for the late survival benefit following the long-term results of randomized trials [3, 5–7]. The known early benefit of EVAR seems to be lost after several years [6, 7]. However, the OVER trial demonstrated non-consistent findings with the other 2 randomized trials [5]. Survival rates and identification of the predictors of late mortality after EVAR are important key factors to be assessed to ensure the real benefit of EVAR. Moreover, real world data along with randomized trials should be taken into consideration to make interpretations about outcomes and survival.

Aim

The aim of this paper is to emphasize the survival rates and predictors of reduced survival after EVAR procedure performed by a single team of endovascular surgery.

Material and methods

Patients

All patients who underwent endovascular AAA repair between January 2013 and December 2019 were identified retrospectively from the database of hospital records. Patient demographics, perioperative variables, and early and midterm outcomes were recorded from the hospital database and death certificates. This study follows the Declaration of Helsinki and the study design and protocol were reviewed and approved by the Institutional Review Board (Ankara Sehir Hastanesi, 1 Nolu Klinik Araştırmalar Etik Kurulu Baskanlığı, E1-19-161). The requirement for informed consent was waived due to the retrospective nature of the study.
consent was waived due to the retrospective nature of the study.

Indications for EVAR included (1) AAA > 5.5 cm in maximum diameter, (2) saccular type of aneurysms, and (3) symptomatic aneurysms. Patients with hostile neck (defined as neck length ≤ 10 mm and/or reverse conical shaped necks) were all included in the study.

**EVAR procedure**

All EVAR procedures were performed in a hybrid operating room by a specific team of cardiovascular surgery. The unibody endografts were mainly used in the early period of the study. In more recent years, modular endografts have been used in our practice. The devices used in this study were the Ankura™ AAA (Lifetech) in 89 (40.1%) patients, the AFX® (Endologix) in 68 (30.6%) patients, the Endurant™II (Medtronic) in 58 (26.1%) patients, the Gore® Excluder® (Gore) in 5 (2.3%) patients, and the E-vita Abdominal XT (Jotec) in 2 (0.9%) patients.

The procedures were performed in the hybrid room under general (169 patients, 76.1%) or loco-regional anaesthesia (53 patients, 23.9%), based on the preference of the surgical team, anaesthesiologist, and patient. Modular endografts were deployed in standard fashion, and the technique for unibody endograft deployment has been previously described [8]. The Endologix AFX® device (unibody) consists of a main bifurcated unibody and a proximal aortic extension. This endograft is the only graft with anatomical fixation at the aortic bifurcation. The aortic extension is placed at the infrarenal position. Completion angiography was performed after the procedure. Type 1 endoleaks were treated by balloon angioplasty and placement of an extension cuff if needed. Type 2 endoleaks were followed.

**Postoperative surveillance**

Postoperative evaluation consisted of clinical and radiological assessment at discharge, 1 month, 6 months, 12 months, and annually thereafter. Computed tomographic examination and Doppler ultrasonography were performed at 1 month. If there were no type 1 or 3 endoleaks at first evaluation, subsequent assessments of endoleak and sac diameters were performed only by Doppler ultrasonography. Type 2 endoleaks were also assessed only by Doppler ultrasonography, because they are accepted as benign endoleaks in the absence of sac enlargement. If there was suspicion of sac enlargement at ultrasonographic examination, this finding was checked by tomography. Sac enlargement was defined as minimum of 5 mm enlargement compared to the preoperative diameter. Contrast angiography was performed at the hybrid room only when a secondary intervention was needed.

**Estimating the possible predictors for survival**

Possible predictors were assessed by 2 commonly used risk models for vascular surgery: the Vascular Quality Initiative and the Vascular Study Group of New England risk prediction models [9–11]. The combined possible predictors of these 2 risk models were analysed in the current study as follows. The predefined patient demographics (age as a continuous variable, gender, and comorbid factors such as diabetes, chronic obstructive pulmonary disease, and concomitant cardiac disease) were identified. Urgent repair was defined as symptomatic aneurysm treated within 24–48 hours of admission. Preoperative renal insufficiency was defined as creatinine level ≥ 1.8 mg/dl, and preoperative anaemia was defined as haematocrit values below 30%. Furthermore, aneurysm diameter was categorized as < 6.0 cm or ≥ 6.0 cm [12].

**Statistical analysis**

The variables were investigated using visual (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk test) to determine the normality of their distribution. Normally distributed continuous variables were expressed as mean ± standard deviation (SD) or median values with range if not normally distributed. Categorical variables were expressed as number and percentages. Demographic parameters, operating variables, and follow-up data were compared using the Mann-Whitney U test and χ² test. Wilcoxon test was conducted to analyse pre-operative and follow-up diameter of aneurysm sac. Kaplan-Meier analysis was conducted to demonstrate freedom from all-cause mortality and freedom from secondary interventions. The hazard ratio (HR) and 95% confidence intervals (CI) were estimated with different Cox proportional-hazard models to estimate the independent predictors of survival with adjustment of the predefined possible risk factors. A p-value of < 0.05 was considered to be statistically significant, and all statistical analyses were performed using the SPSS for Windows version 15.0 statistical software program (SPSS Inc., Chicago, IL, USA).

**Results**

A total of 222 patients underwent EVAR procedure in a 7-year period, and the procedures were carried out by the same team of cardiovascular surgeons. Baseline characteristics of the patients are summarized in Table I. The median age of the patients was 70 years (range: 46–92 years) and the study population was predominantly male (202 patients, 91%).

The median stay in the intensive care unit and in the hospital was 4 hours (range: 2–240 hours) and 2 days (range: 1–20 days), respectively. Perioperative features are reviewed in Table II.

In-hospital mortality was 1.8% (4 patients out of 222). Follow-up was available in all 218 survivors. Excluding 4 in-hospital mortalities, routine follow-up of remainders was included in the outcome assessment. The median follow-up period was 20 months (range: 1–80 months). The follow-up data are shown in Table III.

Five-year freedom from any endoleak was 65% with a 95% confidence interval (CI) of 54.3–74.9%. On the other
What factors counteract mid-term survival following endovascular repair of abdominal aortic aneurysms?

Hand, freedom from type 1a endoleaks, type 1b endoleaks, type 2 endoleaks, and type 3 endoleaks was 97.5% (95% CI: 95.1–99.9%), 92.5% (95% CI: 85.2–99.8%), 83.9% (95% CI: 74.1–93.7%), and 86.5% (95% CI: 75.5–97.5%), respectively.

There were 36 (16.5%) late deaths. Kaplan-Meier survival analysis revealed that overall survival at 1, 3, and 5 years was 93%, 81%, and 62%, respectively (Figure 1). Freedom from secondary intervention was 96%, 89%, and 82% respectively for 1, 3, and 5 years (Figure 2). Indications for secondary intervention (endovascular or open) were type III endoleak (6 patients), stent-graft limb thrombosis (4 patients), type Ib endoleak (4 patients), type Ia endoleak (3 patients), and vascular access problems (2 patients) (Table III).

Aneurysm sac diameter tended to be decreased after the procedure regarding to the preoperative measurements (from median 60 mm to 58 mm, p = 0.047). At the follow-up period, 86% of aneurysms were detected to be decreased in size or remained stable, when considering an increase of 5 mm of diameter as an enlargement.

**Predictors of survival**

Multivariate Cox regression models revealed that the independent predictors for late mortality were the creatinine ≥ 1.8 mg/dl (adjusted HR = 2.68; 95% CI: 1.21–6.42; p = 0.027), hemoglobin < 10 g/dl (adjusted HR = 3.38; 95% CI: 1.16–9.90; p = 0.026), ejection fraction < 30% (adjusted HR = 5.67; 95% CI: 1.29–24.86) and AAA diameter ≥ 6.0 cm (adjusted HR = 2.20; 95% CI: 1.01–4.81; p = 0.049) (Table IV). Age, gender, and symptomatic status of the patient did not interfere with the late survival of the patients. For further analysis, follow-up variables such as endoleak presence, endoleak type, reintervention, and sac enlargement (> 5 mm) were also assessed by hazard models.

### Table I. Baseline characteristics of the patients

| Parameter                          | n (%) or median (range) (N = 222) |
|------------------------------------|-----------------------------------|
| Age [years]                        | 70 (46–92)                        |
| Male gender                        | 202 (91.0)                        |
| ASA grade:                         |                                   |
| 1                                  | 15 (6.8)                          |
| 2                                  | 94 (42.3)                         |
| 3                                  | 82 (36.9)                         |
| 4                                  | 31 (14.0)                         |
| Hypertension                       | 149 (67.1)                        |
| Diabetes                           | 59 (26.6)                         |
| Hyperlipidaemia                    | 66 (29.7)                         |
| Chronic obstructive pulmonary disease | 71 (32.0)                       |
| Renal disease                      | 23 (10.4)                         |
| Atherosclerotic cardiac disease/heart failure | 105 (47.3)              |
| Smoking                            | 99 (44.6)                         |
| Malignancy                         | 13 (5.9)                          |
| Ejection fraction (%)              | 55 (20–67)                        |
| AAA diameter [mm]                  | 60 (33–116)                       |
| ≥ 6.0 cm                           | 119 (57.8)                        |

AAA – abdominal aortic aneurysm, ASA – American Society of Anesthesiologists.

### Table II. Perioperative features

| Features                                              | n (%) or median (range) (N = 222) |
|-------------------------------------------------------|-----------------------------------|
| General anaesthesia                                   | 169 (76.1)                        |
| Local/regional anaesthesia                            | 53 (23.9)                         |
| Type of endograft:                                     |                                   |
| Unibody (AFX® (Endologix))                            | 68 (30.6)                         |
| Modular:                                              | 154 (69.4)                        |
| Ankura™ AAA (Lifetech)                                | 89 (40.1)                         |
| Endurant™II (Medtronic)                               | 58 (26.1)                         |
| Gore® Excluder® (Gore)                                | 5 (2.3)                           |
| E-vita Abdominal XT (jotec)                            | 2 (0.9)                           |
| Aorto-uni-iliac endograft ± fem-fem bypass            | 4 (1.8)                           |
| Duration of procedure [minutes]                       | 120 (90–360)                      |
| Fluoroscopy time [minutes]                            | 16 (6–78)                         |
| Amount of contrast agent [ml]                         | 60 (20–160)                       |
| Length of intensive care unit stay [hours]            | 4 (2–240)                         |
| Length of hospital stay [days]                        | 2 (1–20)                          |
| In-hospital mortality                                 | 4 (1.8)                           |

### Table III. Follow-up data

| Data                                              | n (%) or median (range) (N = 218) |
|---------------------------------------------------|-----------------------------------|
| Reintervention                                    |                                   |
| Endoleaks:                                        |                                   |
| Type Ia                                            | 35 (16.1)                         |
| Type Ib                                           | 3 (1.4)                           |
| Type Ia proximal extensions                       | 3 untreated                       |
| Type Ib distal extensions                          | 4 untreated                       |
| Type II                                           | 17 (7.8)                          |
| Type II untreated (follow-up)                     | 3 untreated (patient preference)  |
| Type III                                          | 9 (4.1)                           |
| Type III open conversion                           | 4 open conversion                 |
| Type III untreated (follow-up)                    | 2 endovascular relining           |
| Limb occlusion                                    | 6 (2.8)                           |
| Limb occlusion femoro-femoral bypasses            | 4 femoro-femoral bypasses         |
| Late conversion to open surgery                    | 4 (1.8)                           |
| Secondary intervention                             | 19 (8.7)                          |
| Late mortality                                     | 36 (16.5)                         |
| 2 untreated                                        |                                   |
Among these covariates, sac enlargement was found to be related with survival only in univariate analysis (HR = 3.78, 95% CI: 1.15–12.45; \( p = 0.029 \)).

**Discussion**

This report presents the mid-term outcome (median follow-up of 20 months) and predictors of survival after endovascular procedures with the use of all type of available endografts for the treatment of AAA by our single endovascular team. Freedom from all-cause mortality was 93% at 1 year, 81% at 3 years, and 62% at 5 years. The main predictors of lower survival rates after EVAR were poor ventricular function, aneurysms above 6 cm, and various comorbidities such as decreased renal function and anaemia.

In the past 2 decades, EVAR has increasingly become the standard treatment modality for non-complex infrarenal AAA [2]. EVAR has numerous advantages, especially in early survival benefit compared to open surgery, including the fact that the procedure has a minimally invasive nature and has a shorter recovery period.

During a median follow-up of 20 months 36 (16.5%) deaths occurred in our study population. The 5-year overall mortality was documented as 73.6% in a meta-analysis of 4 randomized trials [3]. The main controversy of this
What factors counteract mid-term survival following endovascular repair of abdominal aortic aneurysms?

The results of our study are nevertheless reliable in high-volume reports [19, 28, 35–37]. The other confounding issue was the male predominance in our study (91%), which may impede the clarification of results regarding gender.

Alternatively, overall all-cause mortality in the midterm was significantly 3 times lower for the patients without renal disease or anaemia. Saratzis et al. concluded that impaired renal function was independently associated with an increase mortality following EVAR [30]. Similarly, Khashram et al. identified baseline renal impairment (creatinine > 1.7 mg/dl) as an important predictor of survival [28]. Additionally, there are several other studies reporting hazard ratios between 1.6 and 2.1, and confirming the results of our study [34, 38, 39]. On the other hand, concerning anaemia, a few single-centre observational studies have reported an association with reduced mid- and long-term survival [38, 40]. Another observational study regarding severe anaemia (< 10 gr/dl), which is similar to our definition, reported 2.6-fold increased risk of in-hospital mortality after EVAR [41]. Furthermore, our study is unique given that poor midterm survival is associated preoperative severe anaemia (HR = 3.4). Anaemia may be associated with a diminished cardiac reserve and other comorbid conditions. The underlying condition may be addressed to overcome this condition.

This study includes some notable limitations. Firstly, these results were analysed retrospectively and evaluated from a single endovascular team, which may have caused a selection bias. The overall number of the study population was relatively low. Secondly, unfortunately, the cause of late deaths could not be identified for some patients. Therefore, analysis for aneurysm-related death and non-aneurysm-related death could not be constructed for this study. Lastly, considerably short follow-up time may be a limitation to assess the predictors of survival accurately. On the other hand, projection of 5 year survival of this patient cohort is comparable to the literature.
Conclusions

The outcomes of EVAR patients in the current study demonstrates safety and acceptable durability of the endografts in AAA patients at 5 years with a survival rate of over 60% and freedom from secondary intervention exceeding 80%. Large aneurysms, low ejection fraction, poor renal function, and anaemia are independent predictors of reduced survival after endovascular repair of the aneurysm. Longer-term follow-up is expected to be reported through 10 years.

Disclosure

The authors report no conflict of interest.

References

1. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, Mastracci TM, Moll M, Murad MH, Nguyen LL, Oederich GS, Patel MS, Schermerhorn ML, Stames BW. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg 2018; 67: 2-77.e2.

2. Wanghainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, Dick F, van Herwaarden J, Karkos C, Koelemay M, Kibbelaar T, Loftus I, Mani K, Melissena N, Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Beccerin JP, Greenhalgh RM, EVAR-1, DREAM, OVER and ACE Trialists. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for open repair for abdominal aortic aneurysm over 5 years. Br J Surg 2017; 104: 166-178.

3. Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Beccerin JP, Greenhalgh RM, EVAR-1, DREAM, OVER and ACE Trialists. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for open repair for abdominal aortic aneurysm over 5 years. Br J Surg 2017; 104: 166-178.

4. Broos PPHL, W’t Mannetje Y, Stokmans RA, Houterman S, Corte G, Cuyvers WS, Bower TC. Clinical presentation, comorbidities, and age but not female gender predict survival after endovascular repair of abdominal aortic aneurysm. J Vasc Surg 2015; 62: 1125-1133.e1122.

5. Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg Jr FT, Matsunouchi H. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg 2019; 57: 8-93.

6. Powell JT, Sweeting MJ, Ulug P, Blankensteijn JD, Lederle FA, Beccerin JP, Greenhalgh RM, EVAR-1, DREAM, OVER and ACE Trialists. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for open repair for abdominal aortic aneurysm over 5 years. Br J Surg 2017; 104: 166-178.

7. van Schaik TG, Yeung KK, Verhagen HJ, de Bruin JL, van Sambeek MRH, Hinchliffe RJ, Verhagen HJM. Anatomic predictors for late mortality after standard endovascular aneurysm repair. J Vasc Surg 2018; 67: 2126-2135.

8. Avcı T, Askun G, Boğaçhan Akkaya B, Ece Çelikten A, Salman N, Utku Ünal E, Fourneau K, Lane J, Landon BE, Long-term outcomes of abdominal aortic aneurysm repair using the Cook Zenith endograft. J Vasc Surg 2011; 54: 48-57.e2.

9. Bos WT, Tiellieu IF, Zeebregts CJ, Prins TR, van den Dungen JJ, Verhoeven EL. Results of endovascular abdominal aortic aneurysm repair with the Zenith stent-graft. Eur J Vasc Endovasc Surg 2008; 36: 653-660.

10. Wilsinowski B, Barnes M, Jenkins J, Boyne N, Kruger A, Walker PJ. Predictors of outcome after elective endovascular abdominal aortic aneurysm repair and external validation of a risk prediction model. J Vasc Surg 2011; 54: 644-653.

11. Gloviczki P, Huang Y, Oederich GS, Duncan AA, Kalra M, Fleming MD, Harnsen WS, Bower TC. Clinical presentation, comorbidities, and age but not female gender predict survival after endovascular repair of abdominal aortic aneurysm. J Vasc Surg 2015; 61: 853-861.e852.

12. Oliveira NFG, Ultee K, van Rijn MJ, Pinto JP, Raa ST, Gonçalves FB, Hoeks SE, Verhagen HM. Anatomic predictors for late mortality after standard endovascular aneurysm repair. J Vasc Surg 2019; 69: 1444-1451.

13. Marques-Rios G, Oliveira-Pinto J, Mansilha A. Predictors of long-term mortality following elective endovascular repair of abdominal aortic aneurysms. Int Angiol 2018; 37: 277-285.

14. Young ZZ, Balciuniškis R, Ashriff H, Diks D, Esce A, Ellis JL, Glöckl RJ, Doyle AJ, Raman K, Stoner MC. Aortic anatomic severity grade correlates with midterm mortality in patients undergoing abdominal aortic aneurysm repair. Vasc Endovascular Surg 2019; 53: 299-296.

15. Jones DW, Deery SE, Schneider DB, Rybin DV, Siracuse JJ, Farber A, Schermerhorn ML, Vascular Quality Initiative. The Vascular Quality Initiative Carotid Stenosis Repair Procedure: Revision of the Vascular Quality Initiative Carotid Stenosis Treatment Protocol. J Vasc Surg 2019; 70: 159-164.

16. Kramer MS, Schneidman AL, Bower TC. Candidate selection for endovascular aneurysm repair using the Endologix Aneurysm Analysis Management System (EAMS). J Vasc Surg 2017; 65: 48-57.e2.

17. Bos WT, Tiellieu IF, Zeebregts CJ, Prins TR, van den Dungen JJ, Verhoeven EL. Results of endovascular abdominal aortic aneurysm repair with the Zenith stent-graft. Eur J Vasc Endovasc Surg 2008; 36: 653-660.

18. Landon BE, Long-term outcomes of abdominal aortic aneurysm repair using the Cook Zenith endograft. J Vasc Surg 2011; 54: 48-57.e2.

19. Bos WT, Tiellieu IF, Zeebregts CJ, Prins TR, van den Dungen JJ, Verhoeven EL. Results of endovascular abdominal aortic aneurysm repair with the Zenith stent-graft. Eur J Vasc Endovasc Surg 2008; 36: 653-660.

20. Oliveira NFG, Ultee K, van Rijn MJ, Pinto JP, Raa ST, Gonçalves FB, Hoeks SE, Verhagen HM. Anatomic predictors for late mortality after standard endovascular aneurysm repair. J Vasc Surg 2019; 69: 1444-1451.

21. Marques-Rios G, Oliveira-Pinto J, Mansilha A. Predictors of long-term mortality following elective endovascular repair of abdominal aortic aneurysms. Int Angiol 2018; 37: 277-285.

22. Young ZZ, Balciuniškis R, Ashriff H, Diks D, Esce A, Ellis JL, Glöckl RJ, Doyle AJ, Raman K, Stoner MC. Aortic anatomic severity grade correlates with midterm mortality in patients undergoing abdominal aortic aneurysm repair. Vasc Endovascular Surg 2019; 53: 299-296.

23. Jones DW, Deery SE, Schneider DB, Rybin DV, Siracuse JJ, Farber A, Schermerhorn ML, Vascular Quality Initiative. The Vascular Quality Initiative Carotid Stenosis Treatment Protocol. J Vasc Surg 2019; 70: 159-164.

24. Kramer MS, Schneidman AL, Bower TC. Candidate selection for endovascular aneurysm repair using the Endologix Aneurysm Analysis Management System (EAMS). J Vasc Surg 2017; 65: 48-57.e2.

25. Piffaretti G, Mariscalco G, Riva F, Fontana F, Carratelli F, Castelli R. Abdominal aortic aneurysm repair: long-term follow-up of endovascular versus open repair. Arch Med Sci 2010; 7: 273-282.

26. Schlüsser FN, Vaartjes I, van der Heijden GMJG, Moll FL, Verhagen HIM, Muhs BE, de Borst GJ, Groenestege A TT, Kardaun JWPF, de Bruijn A. Mortality after elective abdominal aortic aneurysm repair. Ann Surg 2010; 251: 158-164.

27. Mastracci TM, Greenberg RK, Hernandez AE, Morales C. Defining risk in endovascular aneurysm repair. J Vasc Surg 2010; 51: 1088-1095.e1081.

28. Khasham M, Jenkins JS, Jenkins J, Kruger AJ, Boyne NS, Foster WI, Walker PJ. Long-term outcomes and factors influencing late survival following elective abdominal aortic aneurysm repair: a 24-year experience. Vascular 2016; 24: 115-125.

29. Lifeline Registry of EVAR Publications Committee. Lifeline registry of endovascular aneurysm repair: long-term primary outcome measures. J Vasc Surg 2005; 42: 1-10.

30. Sarafides A, Sarafides K, Molas N, Sarafides N, Konstantinidis N, Kitas G. Improved renal function is associated with mortality and morbidity after endovascular abdominal aortic aneurysm repair. J Vasc Surg 2013; 58: 879-885.

31. Tsilimparis N, Mitakidou D, Hanack U, Deussing A, Yousefi S, Rücker R. Effect of preoperative aneurysm diameter on long-term survival after endovascular aortic aneurysm repair. Vasc Endovasc Surg 2012; 46: 530-535.

32. Egrova NN, Vounouka AG, McKinsey JF, et al. Effect of gender on long-term survival after abdominal aortic aneurysm repair based on results from the Medicare national database. J Vasc Surg 2011; 54: 1-12.e16.
What factors counteract mid-term survival following endovascular repair of abdominal aortic aneurysms?

33. Mehta M, Byrne WI, Robinson H, Roddy SP, Paty PS, Kreienberg PB, Feustel P, Darling III RC. Women derive less benefit from elective endovascular aneurysm repair than men. J Vasc Surg 2012; 55: 906-913.

34. Grootenboer N, Hunink MGM, Hendriks JM, van Sambeek MRHM, Buth J, Collaborators E. Sex differences in 30-day and 5-year outcomes after endovascular repair of abdominal aortic aneurysms in the EUROSTAR study. J Vasc Surg 2013; 58: 42-49.e41.

35. Lee H, Clair D, Ouriel K. Ten-year comparison of all-cause mortality after endovascular or open repair of abdominal aortic aneurysms: a propensity score analysis. World J Surg 2012; 37: 680-687.

36. de Bruin JL, Baas AF, Heymans MW, Buimer MG, Prinsen M, Grobbee DE, Blankenstein ID; DREAM Study Group. Statin therapy is associated with improved survival after endovascular and open aneurysm repair. J Vasc Surg 2014; 59: 39-44.e31.

37. Lo RC, Bensley RP, Hamdan AD, Wyers M, Adams JE, Schermerhorn ML. Gender differences in abdominal aortic aneurysm presentation, repair, and mortality in the Vascular Study Group of New England. J Vasc Surg 2013; 57: 1261-1268.e1265.

38. Diehm N, Benenati JF, Becker GJ, Quesada R, Tsoukas AI, Katzen BT, Kovacs M. Anemia is associated with abdominal aortic aneurysm (AAA) size and decreased long-term survival after endovascular AAA repair. J Vasc Surg 2007; 46: 676-681.

39. Kertai MD, Boersma E, Westerhout CM, van Domburg R, Klein J, Bax JJ, van Urk H, Poldermans D. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116: 96-103.

40. Ohrlander T, Dencker M, Acosta S. Morphological state as a predictor for reintervention and mortality after EVAR for AAA. Cardiovasc Intervent Radiol 2012; 35: 1009-1015.

41. Dakour-Aridi H, Nejim B, Locham S, Alshwaily W, Malas MB. Anemia and postoperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms. J Vasc Surg 2019; 69: 738-751.e732.